Press Releases

PASADENA, Calif. --(BUSINESS WIRE)--Mar. 4, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference – March 6, 2024 Type: Fireside Chat Presentation Date: March 6, 2024

- Conference Call and Webcast Today, February 6, 2024 , at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Feb. 6, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023 .

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 22, 2024-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024 , at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023 .

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 5, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024 , it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”).

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 3, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before